Fig. 3
From: Anti-inflammatory and immune-enhancing effects of enzyme-treated royal jelly
Cell viability of immune cells treated with ERJ. (A) Viability of spleen cells treated with ERJ for 24 or 48 h. ERJ enzyme-treated royal jelly, RJ non-enzyme-treated royal jelly. Data are expressed as mean ± SE (n = 3). (B) Cell viability of spleen cells treated with RJ in the absence or presence of the indicated mitogens for 24 h. ERJ enzyme-treated royal jelly, RJ non-enzyme-treated royal jelly. Data are expressed as mean ± SE (n = 10).*p < 0.05; ***p < 0.001, compared with vehicle. $$$p < 0.001, compared with RJ